Digestive Diseases and Sciences

, Volume 64, Issue 2, pp 367–372 | Cite as

Missed Opportunities for Screening and Surveillance of Barrett’s Esophagus in Veterans with Esophageal Adenocarcinoma

  • Tariq A. Hammad
  • Aaron P. Thrift
  • Hashem B. El-SeragEmail author
  • Nisreen S. Husain
Original Article



Barrett’s esophagus (BE) is the premalignant lesion of esophageal adenocarcinoma (EAC) and is the target of early detection and prevention efforts for EAC.


We sought to evaluate what proportion and temporal trends of EAC patients had missed opportunities for screening and surveillance of BE.


Our study included 182 patients with EAC at the Michael E. DeBakey VA Medical Center in Houston, Texas, between 02/2005 and 09/2017. We conducted a retrospective audit of patients’ medical records for any previous upper endoscopies (EGDs) for screening or surveillance of BE prior to their EAC diagnosis.


The mean age of the cohort was 67.3 years (SD = 9.5); 99.5% of patients were male, and 85.2% were white. Only 45 patients (24.7%) had EGD at any time prior to the cancer diagnosing EGD, of whom 29 (15.9% of all EAC cases) had an established BE diagnosis. In the 137 patients with no prior EGD, most (63.5%) had GERD or were obese or ever smokers. There were no changes in patterns over time. For the 29 patients with prior established BE, 22 (75.8%) were diagnosed with EAC as a result of surveillance EGD. Patients with prior established BE were more likely to be diagnosed at 0 or I stage (p < 0.001) and managed with endoscopic or surgical modalities (p < 0.001) than patients without prior BE.


Despite having established risk factors for BE, the majority of EAC patients had no prior EGD to screen for BE. BE screening may represent the largest missed opportunity to reduce EAC mortality.


Esophageal adenocarcinoma Barrett’s esophagus Screening and surveillance Esophagogastroduodenoscopy (EGD) Quality improvement GERD Guidelines 


Author’s contribution

TAH acquired, analyzed, and interpreted the data and drafted the manuscript. APT analyzed and interpreted the data, drafted the manuscript, and critically revised the manuscript for important intellectual content. HBE and NSH were involved in study concept and design, drafting of the manuscript, and the critical revision of the manuscript for important intellectual content. All authors approved the final version of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest regarding this paper.

Supplementary material

10620_2018_5336_MOESM1_ESM.docx (80 kb)
Supplementary material 1 (DOCX 79 kb)


  1. 1.
    Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012;23:3155–3162.CrossRefGoogle Scholar
  2. 2.
    Rustgi AK, El-Serag HB. Esophageal carcinoma. New Engl J Med. 2014;371:2499–2509.CrossRefGoogle Scholar
  3. 3.
    Thrift AP. The epidemic of oesophageal carcinoma: where are we now? Cancer Epidemiol. 2016;41:88–95.CrossRefGoogle Scholar
  4. 4.
    Maret-Ouda J, El-Serag HB, Lagergren J. Opportunities for preventing esophageal adenocarcinoma. Cancer Prev Res. 2016;9:828–834.CrossRefGoogle Scholar
  5. 5.
    Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of Gastroenterology. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50. Erratum in: Am J Gastroenterol. 2016;111:1077.Google Scholar
  6. 6.
    American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, lnadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084–1091.Google Scholar
  7. 7.
    ASGE Standards of Practice Committee, Muthusamy VR, Lightdale JR, et al. The role of endoscopy in the management of GERD. Gastrointest Endosc. 2015;81:1305–1310.CrossRefGoogle Scholar
  8. 8.
    EI-Serag HB, Naik AD, Duan Z, et al. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett’s oesophagus. Gut. 2016;65:1252–1260.CrossRefGoogle Scholar
  9. 9.
    Saxena N, Inadomi JM. Effectiveness and cost-effectiveness of endoscopic screening and surveillance. Gastrointest Endosc Clin N Am. 2017;27:397–421.CrossRefGoogle Scholar
  10. 10.
    Thrift AP, Kendall BJ, Pandeya N, Whiteman DC. A model to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2013;11:138–144.e2.CrossRefGoogle Scholar
  11. 11.
    Shao-Hua X, Jesper L. A model for predicting individuals’ absolute risk of esophageal adenocarcinoma: moving toward tailored screening and prevention. Int J Cancer. 2016;138:2813–2819.CrossRefGoogle Scholar
  12. 12.
    Modiano N, Gerson LB. Risk factors for the detection of Barrett’s esophagus in patients with erosive esophagitis. Gastrointest Endosc. 2009;69:1014–1020.CrossRefGoogle Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2018

Authors and Affiliations

  • Tariq A. Hammad
    • 1
  • Aaron P. Thrift
    • 2
  • Hashem B. El-Serag
    • 1
    • 3
    Email author
  • Nisreen S. Husain
    • 1
    • 3
  1. 1.Section of Gastroenterology and Hepatology, Department of MedicineBaylor College of Medicine Medical CenterHoustonUSA
  2. 2.Section of Epidemiology and Population Sciences, Department of MedicineBaylor College of MedicineHoustonUSA
  3. 3.Section of Gastroenterology and HepatologyMichael E. DeBakey VA Medical Center (MEDVAMC)HoustonUSA

Personalised recommendations